Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Show patients their plaques, cut cholesterol?

NCT ID NCT06413641

Disease control Sponsor: Aarhus University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether showing people their own coronary CT scans can motivate them to lower their LDL cholesterol and reduce side effects from statins. 273 adults with non-obstructive coronary artery disease will be followed for 12 months. The goal is to see if visual feedback helps improve heart health and slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Visualization of coronary CT angiography images
What this could lead to
If it works, this could point toward a simple, low-cost way to help people with early heart disease stick to cholesterol-lowering treatments and slow plaque buildup.
What could go wrong
This is a small, early-stage study (273 people) testing a behavioral intervention, not a drug. Results may not apply to everyone, and the effect on actual heart attacks or survival is not being measured.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 273 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * New diagnosis of nonobstructive coronary artery disease * No known coronary artery disease (no previous coronary revascularization) * Coronary Artery Disease Reporting and Data System (CAD-RADS) score 1-3 * LDL cholesterol \> 2.0 mmol/l * Life expectancy \>3 years * Signed informed consent Exclusion Criteria: * Post CTA test indication for invasive coronary angiography * Non-evaluable CTA exam * Obstructive coronary disease (One or more coronary stenosis ≥70%, left main \>40%) * Ongoing lipid lowering medical treatment (Patients already on lipid lowering medical therapy can be included if the treatment was initiated \<3 months before the time of the CTA test) * BMI \>40 * Renal insufficiency (eGFR \<40 ml/min) * Allergy to iodinated contrast media * Contraindications to statins (Active liver disease Child-Pugh A, B and C, excessive alcohol consumption) * Participation in a cardiac rehabilitation or lifestyle modification program * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Hypercholesterolemia nonobstructive coronary artery disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Non-obstructive coronary atherosclerosis

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, Denmark

  • Bjarne L Nørgaard

    Aarhus, Denmark

  • Gødstrup Hospital

    Gødstrup, Jutland, Denmark

  • Hospital of South West Jutland

    Esbjerg, Denmark

  • Vejle Hospital

    Vejle, 7100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.